Profile data is unavailable for this security.
About the company
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
- Revenue in EUR (TTM)909.92m
- Net income in EUR-38.77m
- Incorporated--
- Employees1.90k
- LocationAlmirall SARonda General Mitre, 151BARCELONA 08022SpainESP
- Phone+34 932913000
- Fax+34 932913681
- Websitehttps://www.almirall.es/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Pharma India Ltd | 143.14m | 17.84m | 1.90bn | 947.00 | 106.75 | 24.22 | 97.70 | 13.31 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
China Medical System Holdings Ltd | 1.02bn | 304.69m | 1.93bn | 5.70k | 6.37 | 0.985 | 5.82 | 1.90 | 1.05 | 1.05 | 3.51 | 6.80 | 0.4517 | 3.42 | 6.19 | 1,510,450.00 | 13.44 | 18.44 | 15.70 | 21.14 | 76.24 | 75.47 | 29.76 | 34.26 | 3.98 | -- | 0.0772 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
Concord Biotech Ltd | 112.36m | 34.04m | 1.95bn | 1.38k | 57.19 | 11.54 | 48.70 | 17.32 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | 7,385,180.00 | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 149.96m | 26.44m | 1.99bn | 1.55k | 74.53 | 6.90 | -- | 13.25 | 0.9769 | 0.9769 | 5.54 | 10.55 | 0.3743 | 1.21 | 4.71 | 764,598.40 | 6.69 | 5.86 | 9.15 | 7.59 | 63.15 | 55.41 | 17.87 | 17.20 | 1.08 | 33.77 | 0.3356 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
Almirall SA | 909.92m | -38.77m | 1.99bn | 1.90k | -- | 1.32 | -- | 2.19 | -0.1797 | -0.1797 | 4.28 | 7.05 | 0.4107 | 1.51 | 6.15 | 477,897.10 | -1.75 | 0.922 | -1.97 | 1.08 | 75.56 | 78.06 | -4.26 | 2.48 | 1.94 | 12.34 | 0.1927 | -- | 3.62 | 3.40 | -998.72 | -- | -23.27 | -- |
Grand Pharmaceutical Group Ltd | 1.24bn | 222.02m | 1.99bn | 10.53k | 8.87 | 1.10 | 7.37 | 1.60 | 0.5356 | 0.5356 | 3.00 | 4.33 | 0.4692 | 2.94 | 10.26 | 999,581.40 | 8.45 | 10.09 | 11.66 | 14.01 | 61.96 | 61.97 | 18.00 | 22.35 | 0.9819 | 22.96 | 0.1831 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
Dermapharm Holding SE | 1.11bn | 56.58m | 2.00bn | 3.50k | 35.33 | 3.43 | 12.19 | 1.79 | 1.05 | 1.05 | 20.69 | 10.81 | 0.5137 | 1.25 | 9.68 | 318,823.00 | 2.51 | 8.68 | 3.01 | 10.06 | 63.32 | 61.94 | 4.89 | 12.31 | 0.7517 | 2.70 | 0.6367 | 54.69 | 10.79 | 14.68 | -53.54 | -3.70 | 9.85 | -- |
Chongqing Taiji Industry Group Co Ltd | 1.96bn | 105.87m | 2.01bn | 12.59k | 18.95 | 4.08 | -- | 1.03 | 1.50 | 1.50 | 27.66 | 6.95 | 1.03 | 3.15 | 5.84 | 1,223,535.00 | 5.77 | 0.7814 | 17.83 | 2.35 | 46.14 | 44.03 | 5.62 | 0.8498 | 0.5315 | 6.12 | 0.5393 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
BrightGene Bio-Medical Technology Co Ltd | 154.20m | 24.85m | 2.02bn | 1.16k | 82.30 | 6.54 | -- | 13.08 | 0.4569 | 0.4569 | 2.87 | 5.75 | 0.2463 | 1.69 | 4.43 | 1,051,700.00 | 3.43 | 6.53 | 4.29 | 7.93 | 54.92 | 56.93 | 13.93 | 19.90 | 1.45 | 4.86 | 0.4787 | 29.31 | 15.94 | 23.68 | -15.51 | 22.56 | 29.13 | -- |
Tonghua Dongbao Pharmaceutical Co Ltd | 381.02m | 143.71m | 2.07bn | 3.20k | 14.48 | 2.21 | -- | 5.43 | 0.5682 | 0.5682 | 1.51 | 3.73 | 0.403 | 0.8622 | 4.57 | 939,125.30 | 15.20 | 18.68 | 15.84 | 19.68 | 79.89 | 78.73 | 37.71 | 39.20 | 5.04 | -- | 0.03 | 41.73 | 10.69 | 2.69 | -26.17 | 6.85 | -14.75 | 4.56 |
Holder | Shares | % Held |
---|---|---|
Wellington Management Co. LLPas of 27 Jun 2024 | 3.24m | 1.55% |
The Vanguard Group, Inc.as of 06 Jun 2024 | 3.12m | 1.49% |
Caixabank Asset Management SGIIC SAas of 31 Dec 2023 | 2.88m | 1.37% |
Oddo BHF Asset Management SASas of 31 May 2024 | 2.67m | 1.28% |
Santander Asset Management SA SGIICas of 31 Dec 2023 | 2.18m | 1.04% |
Norges Bank Investment Managementas of 31 Dec 2023 | 2.10m | 1.00% |
Cobas Asset Management SGIIC SAas of 30 Apr 2024 | 1.72m | 0.82% |
KBC Asset Management NVas of 31 Dec 2023 | 1.26m | 0.60% |
Amundi Asset Management SA (Investment Management)as of 05 Jun 2024 | 1.11m | 0.53% |
Dimensional Fund Advisors LPas of 06 Jun 2024 | 1.11m | 0.53% |